{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:12:01Z","timestamp":1778825521637,"version":"3.51.4"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To determine the effectiveness and tolerability of PARPi maintenance in a real-world patient population. Specifically, to assess duration of PARPi, the rate of secondary malignancies, rate of side effects, and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective review of patients with ovarian, fallopian tube, and primary peritoneal cancer at OhioHealth Riverside Methodist Hospital in Columbus, Ohio was performed. All patients diagnosed since March 2015 were reviewed for eligibility. Data was collected via EMR query and stored in REDCap. Charts were reviewed for multiple data points, including duration of PARPi use, side effects, secondary malignancies, survival, and recurrence. Data were reported descriptively with medians and ranges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ninety-seven patients met inclusion criteria. The median time patients were maintained on a PARPi was 9.8 months. Termination of patient\u2019s PARPi was most often due to recurrence followed by side effects. Fatigue, anemia, and thrombocytopenia were the most common side effects reported. We report a PFS median of 12.5 months and a median OS of 40.6 months following first PARPi exposure. When stratified by homologous recombination deficiency (HRD) status, unadjusted analyses demonstrated longer PFS among HRD-positive patients compared to HRD-negative and HRD-unknown groups; however, this association was not consistently maintained after multivariable adjustment, and no statistically significant difference in OS was observed. There were two secondary malignancies identified in our study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We report similar survival compared to published trials despite shorter courses of therapy and higher rates of discontinuation due to side effects. Although HRD-positive status was associated with improved outcomes in unadjusted analyses, this effect was not sustained after adjustment for confounding variables, underscoring the complexity of these associations in real-world populations. This cohort study emphasizes the need to examine the real-world population for accurate patient guidance and counseling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1771241","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:42:31Z","timestamp":1778823751000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Poly(ADP-ribose) polymerase inhibitor maintenance therapy in ovarian cancer: a single-center retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Sydney","family":"Pence","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ohio Health - Riverside Methodist Hospital","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kayla","family":"Dyson","sequence":"additional","affiliation":[{"name":"Ohio State University College of Medicine","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Waters","sequence":"additional","affiliation":[{"name":"Wright State University Boonshoft School of Medicine","place":["Fairborn, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John O.","family":"Elliott","sequence":"additional","affiliation":[{"name":"Research Institute, Ohio Health - Riverside Methodist Hospital","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kellie","family":"Rath","sequence":"additional","affiliation":[{"name":"Department of Gynecology Oncology, Ohio Health - Riverside Methodist Hospital","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Pierce","sequence":"additional","affiliation":[{"name":"Department of Gynecology Oncology, Ohio Health - Riverside Methodist Hospital","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Harper","sequence":"additional","affiliation":[{"name":"Department of Gynecology Oncology, Ohio Health - Riverside Methodist Hospital","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corinne","family":"Calo","sequence":"additional","affiliation":[{"name":"Department of Gynecology Oncology, Ohio Health - Riverside Methodist Hospital","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aine E","family":"Clements","sequence":"additional","affiliation":[{"name":"Department of Gynecology Oncology, Ohio Health - Riverside Methodist Hospital","place":["Columbus, OH, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01934","article-title":"Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update","volume":"40","author":"Tew","year":"2022","journal-title":"JCO"},{"key":"B2","unstructured":"Summary: Revisions to FDA approvals for PARP inhibitors in the management of ovarian cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: Clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/s1097-2765(01)00174-5","article-title":"BRCA2 is required for homology-directed repair of chromosomal breaks","volume":"7","author":"Moynahan","year":"2001","journal-title":"Mol Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1097-2765(00)80202-6","article-title":"Brca1 controls homology-directed DNA repair","volume":"4","author":"Moynahan","year":"1999","journal-title":"Mol Cell"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32418-2","article-title":"PARP inhibitors for targeted treatment in ovarian cancer","volume":"390","author":"Dizon","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"6002\u2013","DOI":"10.1200\/JCO.2020.38.15_suppl.6002","article-title":"Final overall survival (OS) results from SOLO2\/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation","volume":"38","author":"Poveda","year":"2020","journal-title":"JCO"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30360-4","article-title":"Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database","volume":"8","author":"Morice","year":"2021","journal-title":"Lancet Haematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.03.011","article-title":"Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials","volume":"161","author":"Nitecki","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"598\u2013606","DOI":"10.1136\/ijgc-2022-004190","article-title":"Myeloid neoplasms post PARP inhibitors for ovarian cancer","volume":"33","author":"Caruso","year":"2023","journal-title":"Int J Gynecologic Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104119","article-title":"Real-world outcomes of PARP inhibitor maintenance in advanced ovarian cancer: a focus on disease patterns and treatment modalities at recurrence","volume":"10","author":"Loverro","year":"2025","journal-title":"ESMO Open"},{"key":"B15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13048-026-02021-0","article-title":"Real-world data of PARP inhibitors in first-line maintenance for BRCA-mutated or HRD-positive advanced ovarian cancer: a multicentre retrospective study from India","volume":"19","author":"Yeshala","year":"2026","journal-title":"J Ovarian Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.06.329","article-title":"Real-world evaluation of PARP inhibitor tolerability in advanced ovarian cancer: Retrospective US cohort study (2209)","volume":"176","author":"Simmons","year":"2023","journal-title":"Gynecologic Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2025.100659","article-title":"Real-world outcomes following PARP inhibitor maintenance in ovarian cancer by BRCA status: a retrospective cohort study","volume":"11","author":"Zucker","year":"2026","journal-title":"ESMO Real World Data Digital Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1728766","article-title":"Real-world data-based assessment of therapy-related myeloid neoplasms after poly(ADP-ribose) polymerase inhibitor treatment in ovarian cancer","volume":"16","author":"Uekusa","year":"","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01003","article-title":"A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45)","volume":"40","author":"Monk","year":"2022","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1771241\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:42:33Z","timestamp":1778823753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1771241\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1771241"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1771241","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1771241"}}